BioPharmSignal logoBioPharmSignal

Biotech News

ADMA Biologics Reports Record Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

ADMA Biologics (ADMA)ADMA BiologicsEarnings

FY 2025 Total Revenue of $510 Million, Representing 20% Year-Over-Year Growth FY 2025 ASCENIV Revenue Grew to $363 Million, Representing 51% Year-Over-Year Growth FY 2025 Adjusted Net Income ( 1) of $161 Million, Representing 35% Year-Over-Year Growth FY 2025 Adjusted EBITDA ( 2) of $231 Million,

Related news

ADMAADMA Biologics2026-02-18 12:00 EST

ADMA Biologics to Report Fourth Quarter and Full Year 2025 Financial Results on February 25, 2026

ADMAADMA Biologics2026-08-05 20:05 EST

ADMA Biologics Reports Second Quarter 2026 Financial Results and Provides Business Update

MDXGMiMedx2026-02-25 21:01 EST

MIMEDX Announces Record Fourth Quarter and Full Year 2025 Operating and Financial Results

CHRSCoherus BioSciences, Inc.2026-03-09 20:15 EST

Coherus Oncology Reports Full Year and Fourth Quarter 2025 Financial Results and Provides Business Update

STTKShattuck Labs2026-03-05 11:15 EST

Shattuck Labs Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Business Highlights

CHRSCoherus BioSciences, Inc.2026-03-02 14:30 EST

Coherus Oncology to Report Full Year and Fourth Quarter 2025 Financial Results on March 9, 2026

RXRXRecursion2026-02-25 11:30 EST

Recursion Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

RXRXRecursion2026-02-18 13:30 EST

Recursion to Report Fourth Quarter and Full Year 2025 Business Updates and Financial Results on February 25

MDXGMiMedx2026-02-17 13:00 EST

MIMEDX to Host Fourth Quarter and Full Year 2025 Operating and Financial Results Conference Call on February 25

STTKShattuck Labs2025-11-06 21:30 EST

Shattuck Labs Reports Third Quarter 2025 Financial Results and Recent Business Highlights

View all latest news

ADMA Biologics

Plasma-Derived Biologics ADMA Biologics is a vertically integrated U.S. manufacturer and marketer of plasma-derived immunoglobulin therapies for immunodeficient patients and people at risk of infection. ASCENIV ASCENIV is an intravenous immunoglobulin enriched with antibodies against respiratory syncytial virus. It is positioned for...

Recent company news

ADMAADMA Biologics2026-08-05 20:05 EST

ADMA Biologics Reports Second Quarter 2026 Financial Results and Provides Business Update

ADMAADMA Biologics2026-07-29 11:00 EST

ADMA Biologics to Report Second Quarter 2026 Financial Results on August 5, 2026

ADMAADMA Biologics2026-05-06 20:05 EST

ADMA Biologics Reports First Quarter 2026 Financial Results and Provides Business Update

ADMAADMA Biologics2026-05-04 11:00 EST

ADMA Biologics Announces FDA Approval to Expand the Label for ASCENIV™ to Include Pediatric Immune Compromised Patients Two Years of Age and Older

ADMAADMA Biologics2026-04-29 11:00 EST

ADMA Biologics to Report First Quarter 2026 Financial Results on May 6, 2026

Stock data

Close
10.06 USD
Market cap
1.76B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States